Navigation Links
ADVENTRX Settles Dispute With Former Licensee
Date:6/30/2008

SAN DIEGO, June 30 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) today announced that it settled its dispute with Theragenex, LLC and its Chairman and President and Chief Executive Officer for payments aggregating $600,000, which payments the Company has received in full. The parties have agreed to jointly move to dismiss the underlying arbitration action and all related claims and counterclaims, with prejudice. In addition, in connection with dismissing the arbitration, the Company and Theragenex will release each other from any and all claims related to their past relationship.

In October 2007, the Company filed a demand for arbitration against Theragenex (doing business as TRx Pharma, LLC and/or TRx Pharmaceuticals, LLC) and its founder, Chairman and President and Chief Executive Officer in his individual capacity as the alter ego of Theragenex, seeking damages of up to $10 million with respect to breach of a license agreement, dated October 20, 2006, between the Company and Theragenex. In November 2007, Theragenex responded to the Company's demand, asserting numerous affirmative defenses, counterclaiming intentional misrepresentation, negligent misrepresentation and rescission and seeking a refund of its initial $500,000 payment under the license agreement, plus interest, rescission of the license agreement and that the Company pay its reasonable attorneys' fees and costs associated with the action.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates primarily for the treatment of cancer and infectious disease. The Company seeks to improve the performance and commercial potential of existing treatments by addressing problems associated with these treatment regimens. More information can be found on ADVENTRX's web site at http://www.adventrx.com.


'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
2. ADVENTRX Appoints Vice President of Manufacturing
3. ADVENTRX Creates Executive Vice President Position and Announces New Chief Financial Officer
4. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
5. ADVENTRX Pharmaceuticals to Report Fourth Quarter and Year End 2007 Results
6. Eric K. Rowinsky Joins ADVENTRX Board of Directors
7. ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting
8. ADVENTRX Announces Consolidation of Clinical and Management Positions
9. ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results
10. ADVENTRX Appoints Vice President of Commercialization
11. ADVENTRX Pharmaceuticals to Present at the 2007 BIOInvestor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in ... Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio ... practical tips, tools, and strategies for clinical researchers. , “The landscape of how ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... , June 23, 2016 A person commits a ... crime scene to track the criminal down. An ... Food and Drug Administration (FDA) uses DNA evidence to track ... Sound far-fetched? It,s not. The FDA has increasingly ... support investigations of foodborne illnesses. Put as simply as possible, ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
Breaking Biology Technology:
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
Breaking Biology News(10 mins):